| Cell line name | laNK | |
|---|---|---|
| Synonyms | low affinity NK; CD16-F158.NK-92.05 | |
| Accession | CVCL_VN54 | |
| Resource Identification Initiative | To cite this cell line use: laNK (RRID:CVCL_VN54) | |
| Comments | Population: Caucasian. Characteristics: No longer dependent on IL2. Transfected with: HGNC; 3619; FCGR3A. Transfected with: HGNC; 6001; IL2. Caution: This cell line is exclusively owned and controlled by NantKwest, Inc. NantKwest and its affiliate, Brink Biologics, Inc. are the sole authorized distributors for both commercial and non-commercial research requestors. There are no other authorized commercial and non-commercial suppliers for this cell line. Contact NantKwest and Brink Biologics for information concerning current inventory and cell line use and support. Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178. Cell type: Natural killer cell; CL=CL_0000623. | |
| Disease | Natural killer cell lymphoblastic leukemia/lymphoma (NCIt: C82217) | |
| Species of origin | Homo sapiens (Human) (NCBI Taxonomy: 9606) | |
| Hierarchy | Parent: CVCL_2142 (NK-92) Children:
| |
| Sex of cell | Male | |
| Age at sampling | 50Y | |
| Category | Cancer cell line | |
| Web pages | https://brinkbiologics.com/platform/ | |
| Cross-references | ||
| Encyclopedic resources | Wikidata; Q95981275 | |
| Entry history | ||
| Entry creation | 07-Sep-2018 | |
| Last entry update | 05-Oct-2023 | |
| Version number | 6 | |